Volume 3.32 | Aug 24

Prostate Cell News 3.32 August 24, 2012
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
Clusterin Mediates TGF-β-Induced Epithelial-Mesenchymal Transition and Metastasis via Twist1 in Prostate Cancer Cells
Findings indicated that clusterin (CLU) is an important mediator of transforming growth factor-β (TGF-β)-induced epithelial-mesenchymal transition, and suggested that CLU suppression may represent a promising therapeutic option for suppressing prostate cancer metastatic progression. [Cancer Res] Abstract

Register for Training Course: Air-Liquid Interface Culture of Primary Human Bronchial Epithelial Cells
PUBLICATIONS (Ranked by impact factor of the journal)


14-3-3ζ, a Novel Androgen-Responsive Gene, Is Upregulated in Prostate Cancer and Promotes Prostate Cancer Cell Proliferation and Survival 
Scientists investigated the androgen regulation and functional analysis of 14-3-3ζ in prostate cancer. [Clin Cancer Res] Abstract

Regulation of Expression of Deoxyhypusine Hydroxylase (DOHH), the Enzyme that Catalyzes the Activation of eIF5A, by miR-331-3p and miR-642-5p in Prostate Cancer Cells
Researchers discovered a novel role for miR 331-3p and miR 642 5p in the control of prostate cancer cell growth via the regulation of DOHH expression and eukaryotic translation initiation factor (eIF5A) activity. [J Biol Chem]  Full Article

Diverse Functions of IGF/Insulin Signaling in Malignant and Noncancerous Prostate Cells: Proliferation in Cancer Cells and Differentiation in Noncancerous Cells
Investigators stimulated prostate cancer and noncancerous prostate cells and observed differing responses: while cancer cells responded to insulin-like growth factor (IGF) and insulin exposure by way of enhanced cell proliferation and glucose consumption, basal to luminal differentiation was induced in noncancerous cells. [Endocrinology] Abstract

A Small Molecule Agonist of EphA2 Receptor Tyrosine Kinase Inhibits Tumor Cell Migration In Vitro and Prostate Cancer Metastasis In Vivo
Researchers found that treatment with doxazosin triggered EphA2 receptor internalization, and suppressed haptotactic and chemotactic migration of prostate cancer, breast cancer, and glioma cells. [PLoS One]
Full Article

Androgen Deprivation Induces Senescence Characteristics in Prostate Cancer Cells In Vitro and In Vivo
Scientists investigated the occurrence of senescence in prostate tumor tissue after androgen deprivation therapy. [Prostate] Abstract

Inflammation-Mediated Abrogation of Androgen Signaling: An In Vitro Model of Prostate Cell Inflammation
Scientists established an in vitro model of prostatic inflammation to investigate the loss of androgen receptor-mediated signaling in androgen responsive prostate cell lines. [Mol Carcinogen] Abstract

Does Androgen-Ablation Therapy (AAT) Associated Autophagy Have a Pro-Survival Effect in LNCaP Human Prostate Cancer Cells?
Researchers studied the cellular effects of the anti-androgen bicalutamide on autophagy and its potential impact on response to androgen-ablation therapy alone or combined with docetaxel chemotherapy in human prostate cancer LNCaP cells. [BJU Int] Abstract

Knockdown of Zinc Finger Protein X-Linked Inhibits Prostate Cancer Cell Proliferation and Induces Apoptosis by Activating Caspase-3 and Caspase-9
Scientists found that repression of zinc finger protein X-linked (ZFX) in prostate cancer cells effectively suppressed the cellular proliferation and colony-formation ability, and led to G1 phase cell cycle arrest. Inhibition of ZFX-induced cell apoptosis by activating caspase-1, -3 and -9. [Cancer Gene Ther] Abstract


Cell-Free Circulating Plasma hTERT mRNA Is a Useful Marker for Prostate Cancer Diagnosis and Is Associated with Poor Prognosis Tumor Characteristics
Researchers assessed the usefulness of plasma telomerase reverse transcriptase (hTERT) mRNA as a diagnostic and prognostic tool for prostate cancer and its association with clinicopathological parameters of tumors. [PLoS One] Full Article

Phase II Study of Carlumab, a Human Monoclonal Antibody Against CC-Chemokine Ligand 2, in Metastatic Castration-Resistant Prostate Cancer.
In this phase II, open-label study, patients with metastatic castration-resistant prostate cancer previously treated with docetaxel received a 90-min infusion of 15 mg/kg carlumab q2w. [Invest New Drugs] Abstract

View Lectures, Tools, Protocols and Other Resources on the Human Immunology Portal (www.humanimmunologyportal.com)

Based on your feedback, we’ve added a Reviews section to Prostate Cell News

Medical Strategies for Treatment of Castration Resistant Prostate Cancer (CRPC) Docetaxel Resistant
This review discusses current options and the ongoing trials for second-line treatment of CRPC including chemotherapy, hormonal therapies, antiangiogenetic and immune strategies. [Cancer Biol Ther] Abstract

Patterns of Outcome and Toxicity after Salvage Prostatectomy, Salvage Cryosurgery and Salvage Brachytherapy for Prostate Cancer Recurrences after Radiation Therapy: A Multi-Center Experience and Literature Review
In this overview, five high-volume Dutch centers describe their toxicity and outcome data using different salvage techniques, providing a view on how salvage is performed in clinical practice in the Netherlands. [World J Urol] Abstract


AGH Study Explores Novel Approach to Prostate Cancer Treatment
An innovative course of prostate cancer radiotherapy that pares weeks from treatment time is now being tested in a clinical trial by physicians at Allegheny General Hospital (AGH). [The West Penn Allegheny Health System] Press Release

EDAP Completes Follow-Up Phase and Data Collection for FDA ENLIGHT Trial
EDAP TMS SA provided an update regarding its Ablatherm-High Intensity Focused Ultrasound ENLIGHT U.S. clinical trial for the indication of low risk, localized prostate cancer. [EDAP TMS] Press Release

Team Awarded Nearly $1.5 Million to Develop New Approaches to Treat Cancer
Scientists from The Scripps Research Institute have been awarded approximately $1.5 million from the National Institutes of Health to identify and develop new therapeutic approaches against a broad spectrum of cancers. [The Scripps Research Institute] Press Release




National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW 2nd World Congress on Cell Science & Stem Cell Research
November 12-14, 2012
San Antonio, United States

Visit our events page to see a complete list of events in the prostate cell community.


Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

Research Technologist – Research and Development (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Researcher – Transcriptomic Diagnostic for Prostate Cancer – (University of Leeds)

Postdoctoral Position – Prostate Cancer (BC Cancer Agency)

Postdoctoral Position – Prostate Cancer (Medical University of South Carolina)

Postdoctoral Position – Prostate Molecular Oncology (University of Dublin)

Postdoctoral Position – Prostate Cancer Research (University of Texas Southwestern Medical Center)

Postdoctoral Position – Molecular Biomarkers Research for Prostate Carcinoma (Università degli Studi di Genova)

Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.


Learn more about Prostate Cell News: Archives | Events | Contact Us